Market closedNon-fractional
Cerevel Therapeutics/CERE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cerevel Therapeutics
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
Ticker
CERE
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
355
Website
www.cerevel.com
CERE Metrics
BasicAdvanced
$8.1B
Market cap
-
P/E ratio
-$2.74
EPS
1.47
Beta
-
Dividend rate
Price and volume
Market cap
$8.1B
Beta
1.47
Financial strength
Current ratio
10.22
Quick ratio
10.121
Long term debt to equity
84.822
Total debt to equity
85.445
Interest coverage (TTM)
-46.34%
Management effectiveness
Return on assets (TTM)
-29.79%
Return on equity (TTM)
-92.45%
Valuation
Price to book
14.32
Price to tangible book (TTM)
14.32
Price to free cash flow (TTM)
-20.153
Growth
Earnings per share change (TTM)
8.33%
3-year earnings per share growth (CAGR)
19.12%
What the Analysts think about CERE
Analyst Ratings
Majority rating from 9 analysts.
CERE Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$132M
-0.53%
Profit margin
0.00%
NaN%
CERE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.63
-$0.61
-$0.76
-$0.73
-
Expected
-$0.65
-$0.63
-$0.59
-$0.61
-$0.62
Surprise
-2.86%
-3.51%
27.75%
19.39%
-
CERE News
AllArticlesVideos
The Schall Law Firm Is Performing A Scrutiny Into Cerevel Therapeutics Holdings Inc And Proprietors Of CERE Shares Are Welcomed To Engage
Accesswire·4 weeks ago
The Schall Law Firm Is Carrying Out An Inquiry Into Cerevel Therapeutics Holdings Inc And Possessors Of CERE Shares Are Requested To Be Part Of It
Accesswire·4 weeks ago
The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Holders Of CERE Shares Are Encouraged To Participate
Accesswire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cerevel Therapeutics stock?
Cerevel Therapeutics (CERE) has a market cap of $8.1B as of July 27, 2024.
What is the P/E ratio for Cerevel Therapeutics stock?
The price to earnings (P/E) ratio for Cerevel Therapeutics (CERE) stock is 0 as of July 27, 2024.
Does Cerevel Therapeutics stock pay dividends?
No, Cerevel Therapeutics (CERE) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Cerevel Therapeutics dividend payment date?
Cerevel Therapeutics (CERE) stock does not pay dividends to its shareholders.
What is the beta indicator for Cerevel Therapeutics?
Cerevel Therapeutics (CERE) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Cerevel Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.